INBRAIN Neuroelectronics

About:

INBRAIN Neuroelectronics is a BCI therapeutics company using graphene to build the least invasive and most intelligent neural platform

Website: https://www.inbrain-neuroelectronics.com

Top Investors: European Investment Bank, European Innovation Council, Asabys Partners, Vsquared Ventures, imec.xpand

Description:

INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn.

Total Funding Amount:

102M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Barcelona, Catalonia, Spain

Founded Date:

2019-12-09

Contact Email:

info(AT)inbrain-neuroelectronics.com

Founders:

Anton Guimera, Carolina Aguilar, Jose Garrido, Kostas Kostarelos

Number of Employees:

11-50

Last Funding Date:

2024-10-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai